{
  "id": "61f7cca7882a024a1000002b",
  "type": "yesno",
  "question": "Is Sotatercept effective for Pulmonary Arterial Hypertension?",
  "ideal_answer": "Sotatercept was shown to be effective for Pulmonary Arterial Hypertension.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33789009",
    "http://www.ncbi.nlm.nih.gov/pubmed/33733610"
  ],
  "snippets": [
    {
      "text": "Sotatercept for the Treatment of Pulmonary Arterial Hypertension.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33789009",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Treatment with sotatercept resulted in a reduction in pulmonary vascular resistance in patients receiving background therapy for pulmonary arterial hypertension.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33789009",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotatercept for the Treatment of Pulmonary Arterial Hypertension",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33789009",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Treatment with sotatercept resulted in a reduction in pulmonary vascular resistance in patients receiving background therapy for pulmonary arterial hypertensio",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33789009",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "n hematologic adverse events. One patient in the sotatercept 0.7-mg group died from cardiac arrest.CONCLUSIONS: Treatment with sotatercept resulted in a reduction in pulmonary vascular resistance in patients receiving background t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33789009",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}